文献速递其他结缔组织病类风湿关节炎

JAK抑制剂成功治疗多中心网状组织细胞增生症:病例系列

Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series.
PubMed 文献 · RMD Open · 2026-05-07

本文报告3例多中心网状组织细胞增生症(MRH)患者,均有异质性系统受累,表现为从关节痛到破坏性关节病的炎症性关节炎及面部躯干早期皮肤丘疹。所有患者抗Ro52kD抗体阳性,2例符合干燥综合征标准;传统合成改善病情抗风湿药和TNF抑制剂无效或耐受差,而托法替布和乌帕替尼在关节、皮肤、血管和肺部域均诱导快速持久改善。

要点

  • MRH可表现为侵蚀性关节炎、皮肤丘疹及多系统受累,常伴自身免疫重叠。
  • 传统csDMARDs和TNF抑制剂无效或耐受差时,JAK抑制剂可能有效。
  • 托法替布和乌帕替尼在关节、皮肤、血管及肺部域均显示快速持久改善。

核心结论

  • JAK抑制剂对难治性多系统MRH患者可诱导持续的多域应答,支持JAK-STAT信号在MRH中发挥作用。

研究设计与样本

  • 病例系列,报告3例MRH患者,均有异质性系统受累。

主要发现

  • 所有患者出现炎症性关节炎(从关节痛到破坏性关节病)及主要累及面部和躯干的早期皮肤丘疹。
  • 1例患者有指端微血管病伴硬皮病样毛细血管镜模式,另1例有间质性肺病伴淋巴细胞性肺泡炎。
  • 2例符合干燥综合征标准,所有患者抗Ro52kD抗体阳性。
  • 诊断经组织学证实为CD68阳性组织细胞和多核巨细胞浸润。
  • 传统csDMARDs和TNF抑制剂无效或耐受差,而托法替布和乌帕替尼在关节、皮肤、血管和肺部域诱导快速持久改善。

关键数值与推荐

  • 诊断经组织学证实为CD68阳性组织细胞和多核巨细胞浸润。
  • 2例符合干燥综合征标准,所有患者抗Ro52kD抗体阳性。

临床怎么用

  • 对传统csDMARDs和TNF抑制剂无效或耐受差的难治性多系统MRH,可考虑JAK抑制剂(托法替布或乌帕替尼)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multicentric reticulohistiocytosis (MRH) is a rare non-Langerhans cell histiocytosis characterised by erosive arthritis and papulonodular skin lesions, frequently associated with autoimmune features. Therapeutic strategies remain empirical despite the potentially severe and disabling course. We report three cases of MRH with heterogeneous systemic involvement, all showing sustained, multidomain responses to Janus kinase (JAK) inhibitors.All patients developed inflammatory arthritis, ranging from arthralgia to destructive arthropathy, and early cutaneous papules predominantly affecting the face and trunk. Systemic manifestations included digital microangiopathy with a scleroderma-like capillaroscopic pattern in one patient and interstitial lung disease with lymphocytic alveolitis in another. Two patients fulfilled criteria for Sjögren's syndrome, and all were positive for anti-Sjögren's-syndrome-related antigen A/Ro52kD antibodies, highlighting the autoimmune overlap of MRH.Diagnosis was confirmed histologically by CD68-positive histiocytic and multinucleated giant cell infiltration. Conventional synthetic disease-modifying antirheumatic drugs and tumour necrosis factor inhibitors were ineffective or poorly tolerated, whereas tofacitinib and upadacitinib induced rapid and durable improvement across articular, cutaneous, vascular and pulmonary domains. These observations support a role for JAK-STAT signalling in MRH and suggest JAK inhibition as a rational therapeutic option in refractory multisystem disease.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hilliquin S, Dupin N, Franck N, et al. Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series. RMD Open. 2026. PMID: 42097694. doi:10.1136/rmdopen-2025-006661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。